

Remarks

Applicants request consideration of the above-referenced patent application.

I. Amendments to the specification

The amended portions of the specification are shown on page 2 above. Applicants believe that the amendments to the specification do not introduce new matter and are permissible under MPEP §2163.07. Specifically:

- A. Applicants have amended the paragraph bridging lines 8-14 on page 10 to insert a sequence identification number for the recited nucleotide sequence. Applicants also have enclosed a sequence listing showing the nucleotide sequence recited in the specification (*i.e.*, SEQ ID NO: 1).
- B. Applicants have amended the sentence bridging lines 11-13 on page 10 to recite that the modified T7 primer has 24 thymidines at the 3' end rather than the 5' end. This amendment is supported by the originally filed application at, for example, lines 13-14, which provide the sequence of the modified T7 primer.

II. Claim listing

This Amendment B does not cancel or amend any claims, nor does it add new claims. Thus, claims 1-10 and 12 are pending. All pending claims are shown on pages 3-4 above.

III. Sequence listing

Applicants have enclosed a written sequence listing (on paper) and a sequence listing in computer readable format (on a diskette). Applicants request that the enclosed sequence listing be entered into the application.

IV. Statements under 37 C.F.R. §§1.821(f) and (g)

Applicants state their belief that the information recorded in computer readable format is identical to the written (on paper) sequence listing. Applicants also state their belief that the enclosed sequence listing does not contain new matter.

* * * * *

Applicants authorize the Commissioner to charge \$970 (\$790 for the Request for Continued Examination and \$180 for the Supplemental Information Disclosure Statement) to Deposit Account No. 01-0025. Applicants believe that they do not owe any other fee(s) for this filing. If, however, Applicants do owe such fee(s), the Commissioner is hereby authorized to charge those fee(s) to Deposit Account No. 01-0025. In addition, if there is ever any fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17

U.S. Patent Application No. 10/802,829
Amendment B
February 27, 2007

in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **01-0025**.

Applicants submit that the application is in condition for allowance, and request that it be allowed. Applicants request that the Examiner call the undersigned if any issues arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,
Kempf et al.



Lydia N. Nenow, PTO Reg. No. 52,530
Abbott Laboratories
Dept. 0377, Bldg. AP6A-1
100 Abbott Park Road
Abbott Park, IL 60064
(847) 938-0389 (tel)
(847) 938-2623 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service (Express Mail Label No. **EV 959284222 US**) on **February 27, 2007** with sufficient postage as first class mail (including Express Mail per MPEP §512), and addressed to **Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.



Lydia N. Nenow, PTO Reg. No. 52,530